Drug intelligence / Profile preview

BR1015-2

Development stage: Unknown
Lead developer: Boryung
Administration: Oral

Overview

BR1015-2 is an investigational drug developed by Boryung Pharmaceutical Co., Ltd. It is currently undergoing Phase I clinical trials to evaluate its pharmacokinetics and safety in healthy volunteers. The drug is administered orally as a single tablet, both alone and in co-administration studies with other related compounds such as BR1015, BR1015-1, and BR1015-3. These studies assess its behavior under both fed and fasting conditions.

Beyond the preview

Go deeper on BR1015-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1015-2.

Explore the full profile